New Zealand's Living Cell Technologies Cleared For Phase II Diabetes Trials As Pig Herd Becomes More Famous
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Auckland-based Living Cell Technologies received the green light from New Zealand regulators to proceed with Phase II clinical trials of its lead product Diabecell, based on encapsulated pig insulin-producing cells aimed at normalizing blood glucose levels for people with type 1 diabetes
You may also be interested in...
New Zealand's Living Cell Technologies Closer To Getting Pigs To Market
PERTH, Australia - Auckland-based cell implant company Living Cell Technologies has started working on an animal-derived therapeutics project with the New Zealand government's investment promotion agency, Investment New Zealand
New Zealand's Living Cell Technologies Closer To Getting Pigs To Market
PERTH, Australia - Auckland-based cell implant company Living Cell Technologies has started working on an animal-derived therapeutics project with the New Zealand government's investment promotion agency, Investment New Zealand
J&J Subsidiary Centocor Extends Collaboration With New Zealand's Living Cell Technologies For Encapsulation Technology
PERTH, Australia - Johnson & Johnson subsidiary Centocor has extended its two-year research collaboration with New Zealand-based Living Cell Technologies, and signed on for an exclusive two-year option to license globally LCT's encapsulation technology for human cell lines